Drug-Eluting Beads Loaded With Doxorubicin (DEBDOX) Chemoembolisation Before Liver Transplantation for Hepatocellular Carcinoma: An Imaging/Histologic Correlation Study

Pauwels, Xavier; Azahaf, Mustapha; Lassailly, Guillaume; Sergent, Géraldine; Buob, David; Truant, Stéphanie; Boleslawski, Emmanuel; Louvet, Alexandre; Gnemmi, Viviane; Canva, V.; Mathurin, Philippe; Pruvot, François‐René; Leteurtre, Emmanuelle; Ernst, Olivier; Dharancy, Sébastien

doi:10.1007/s00270-014-0967-1

Cited by 10 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients with HCC within the Milan criteria, bridging therapy is estimated to reduce the dropout rate to 0-10% [56]. Bland, chemotherapeutic, and radiotherapeutic embolization techniques have all shown to be similar bridging therapies in terms of safety and efficacy [57][58][59]. A recently conducted prospective study comparing 90 Y to cTACE in patients with either BCLC stage A or B found longer times to progression: >26 months in the 90 Y group versus 6.8 months in the cTACE group, p = 0.012, (HR 0.122, 95% CI, 0.027-0.557, p = 0.007), but similar tumor necrosis and median survival times.…”

Section: Bridge To Transplantmentioning

confidence: 99%

Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update

Kishore

Bajwa

Madoff

2020

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) represents a significant contributor to cancer-related morbidity and mortality with increasing incidence in both developing and developed countries. Embolotherapy as a locoregional therapeutic strategy consists of trans-arterial or “bland” embolization (TAE), trans-arterial chemoembolization (TACE), and selective internal radiotherapy (SIRT). Trans-catheter arterial therapies can be applied along all stages of HCC, either as an alternative or neoadjuvant to surgical resection/transplantation in very early and early stage HCC or as a palliative option for local disease control in unresectable and advanced stage HCC. In advanced stage HCC, SIRT did not demonstrate superiority in comparison to systemic treatment options in several recent large prospective trials, though for carefully selected patients, may confer improved tolerability with similar disease control rates. The latest embolotherapeutic techniques and literature as they pertain to the management of HCC, as well as future directions, are reviewed in this article.

show abstract

Section: Bridge To Transplantmentioning

confidence: 99%

Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update

Kishore

Bajwa

Madoff

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…43,44 All embolotherapies have shown similar safety and efficacy profiles for patients requiring bridging therapy. [45][46][47] Although there was no difference in OS, a prospective study of patients with either BCLC Stage A or B comparing SIRT to cTACE observed longer times to progression (TTPs) in the SIRT group in comparison to the cTACE group: >26 months in the SIRT group versus 6.8 months in the cTACE group, p ¼ 0.012 (hazard ratio [HR]: 0.122, 95% confidence interval [CI]: 0.027-0.557, p ¼ 0.007). The authors concluded that the longer TTP provided by radioembolization could potentially reduce dropout from transplant waitlists.…”

Section: Bridge To Transplantmentioning

confidence: 99%

Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions

Bajwa

Madoff

Kishore

2020

Digestive Disease Interventions

View full text Add to dashboard Cite

Primary and secondary liver cancers are a major cause of mortality worldwide. Transarterial liver-directed therapy, or embolotherapy, represents an important locoregional treatment strategy for primary and secondary liver tumors. Embolotherapeutic modalities include bland embolization (transarterial embolization), chemoembolization (transarterial chemoembolization), and radioembolization or selective internal radiotherapy. A brief technical overview of embolotherapeutic modalities as well as supportive evidence for the treatment of most common primary and secondary liver tumors will be discussed in this review. Several potential future applications, including synergy with systemic therapy, interventional theranostics, and artificial intelligence will also be reviewed briefly.

show abstract

“…It is generally believed that pre‐TACE treatment could also improve the prognosis after LT . Though many medical centers have studied on this, there is still no definite conclusion . In addition, no meta‐analyses have investigated on this issue.…”

Section: Introductionmentioning

confidence: 99%

“…[8][9][10][11] It is generally believed that pre-TACE treatment could also improve the prognosis after LT. [12][13][14] Though many medical centers have studied on this, there is still no definite conclusion. 15,16 In addition, no meta-analyses have investigated on this issue. Therefore, we conducted the meta-analysis of all available studies to systematically evaluate the effect of preoperative TACE on LT.…”

Section: Introductionmentioning

confidence: 99%

Transarterial chemoembolization prior to liver transplantation for patients with hepatocellular carcinoma: A meta‐analysis

Chen

et al. 2017

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim A debate exists over whether using preoperative transarterial chemoembolization for patients with hepatocellular carcinoma before liver transplantation. Numerous studies have been investigating on this, but there is still no unanimous conclusion about the effect of preoperative transarterial chemoembolization. We conducted the meta‐analysis of all available studies to systematically evaluate the influence of preoperative transarterial chemoembolization on liver transplant. Methods A systematic search was performed by two authors (Si TF. and Guan RY.) through PubMed, Embase, Cochrane, and Science Citation Index Expanded, combined with Manual Retrieval and Cited Reference Search. The searching cut‐off date was 2016/07/31, and all the data obtained were statistically analyzed using Review Manager version 5.1 software (Copenhagen, The Nordic Cochrane Center, The Cochrane Collaboration, 2011) recommended by Cochrane Collaboration. Results The study showed that there was no difference between the experimental group and the control group on perioperative mortality (RR = 1.10, 95% confidence interval (CI) = [0.49–2.48], P = 0.82) or biliary complications (RR = 0.96, 95%CI = [0.66–1.39], P = 0.83). Preoperative transarterial chemoembolization had no obvious effect on improving overall survival (HR = 1.05, 95%CI = [0.65–1.72], P = 0. 83) but would result in a higher rate of vascular complications (RR = 2.01, 95%CI = [1.23–3.27], P = 0.005) and a reduction of disease free survival (HR = 1.66, 95%CI = [1.02–2.70], P = 0.04). Subgroup analysis also revealed that patients from transarterial chemoembolization group in Asia had a much lower overall survival rate (HR = 2.65, 95%CI = [1.49–4.71], P = 0.0009) compared with the control group. Conclusions Considering the possible adverse impacts on liver transplantation and the variation in sensitivity to transarterial chemoembolization, clinicians should be more cautious when considering transarterial chemoembolization as the bridging therapy for patients in the waiting list.

show abstract

Drug-Eluting Beads Loaded With Doxorubicin (DEBDOX) Chemoembolisation Before Liver Transplantation for Hepatocellular Carcinoma: An Imaging/Histologic Correlation Study

Cited by 10 publications

References 29 publications

Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update

Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update

Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions

Transarterial chemoembolization prior to liver transplantation for patients with hepatocellular carcinoma: A meta‐analysis

Contact Info

Product

Resources

About